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Background: Salvia-Nelumbinis naturalis (SNN), initially called Jiangzhi Granula as a formulae of Chinese medicinal
decoction, has been used clinically to treat non-alcoholic fatty liver disease (NAFLD) and related syndromes. The
mechanism of SNN action is unknown.
Methods: HepG2 cells were cultured in lipid-rich media supplemented with chemical components of SNN. Male
Wistar rats (6 weeks of age) were fed a high calorie diet (15% fat, 15% sucrose, and 2% cholesterol) for eight weeks,
and then treated with SNN for four weeks. Body and liver weight, lipids profiles, insulin and glucose levels, glucose
and insulin tolerance were evaluated, the mRNA and protein expression of insulin receptor (InsR), insulin receptor
substrate (IRS) 1/2, protein kinase B (PKB/Akt), protein expression of suppressor of cytokine signaling 3 (SOCS3),
protein kinase C epsilon (PKC ε) in liver tissue were analysed.
Results: Treatment with SNN components in lipid-laden HepG2 cells decreased lipid accumulation. Rats fed with
a HC diet developed hepatosteatosis and accompanied hyperglycemia, hyperinsulinemia, hyperleptinemia, and diabetic
dyslipidemia. Prolonged HC diet feeding resulted in parabolic response in plasma triglyceride (TG) concentrations,
indicative of compromised hepatic production of TG-rich lipoproteins. HC diet feeding also resulted in impaired insulin
sensitivity and hepatic insulin signalling. Administration of SNN extracts alleviated hepatosteatosis and conferred to a
normolipoproteinemia profile in the HC diet-fed rats. The efficacy of SNN extract in improving liver function and insulin
sensitivity was comparable to that of simvastatin or pioglitazone. The improved insulin signaling by SNN treatment was
associated with increased IRS and Akt phosphorylation and decreased SOCS3 expression. However, SNN failed to inhibit
the PKC ε expression in the liver.
Conclusions: SNN is effective in reducing lipid accumulation in HepG2 cells and attenuating hepatosteatosis in HC
diet-fed rats. Reduced hepatic lipid content in the rat liver was associated with improved insulin signalling.
Keywords: Hepatosteatosis, Insulin resistance, Salvia-Nelumbinis naturalisBackground
Hepatosteatosis, i.e. excess accumulation of triglyceride
(TG) in the liver, is the defining feature of non-alcoholic
fatty liver disease (NAFLD). As the epidemic of obesity
has increased worldwide, NAFLD become a critical public
health issue because of its high prevalence, potential
progression to severe liver disease, and association with* Correspondence: jiliver@vip.sina.com
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unless otherwise stated.serious metabolic abnormalities including type 2 diabetes
mellitus, metabolic syndrome, and coronary heart disease
[1]. Previously considered as an abnormality confined to
adult populations, NAFLD, is now an alarming health
issue among obese children [2]. Hence, finding an effective
NAFLD therapy is necessary to alleviate the health burden
caused by this disease.
Insulin resistance is intimately associated with the
pathogenesis of NAFLD, as evidenced by patho-physiologic
studies [3-5]. Insulin binds to its receptor, which results in
the tyrosine phosphorylation of insulin receptor substrate
(IRS)-1and IRS-2, and subsequently activates downstreamLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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kinase B (PKB/Akt), etc. [6]. Impaired insulin signalling,
especially the paradox of selective hepatic insulin resistance
of failing to suppress glucose production but preserved
insulin sensitivity in lipid synthesis aggravates insulin
resistance and contributes to the development of NAFLD,
while regimens that reverse insulin resistance can
ameliorate steatosis [7]. Although numerous studies have
focused on NAFLD, suggested treatments (thiazolidine-
diones, statins) do not always produce satisfied results.
Calorie restriction and exercise can treat simple or
moderate NAFLD effectively, but target drugs are needed
when the disease becomes progressive and severe.
For centuries, natural herbal products derived from
systemic Traditional Chinese Medicine (TCM) theory
and practice have been used to treat nearly all kinds of
ailments in China. Formulae, the form of prescription in
TCM, typically consists of several medicinal herbs, of
which one represents a principal component, and others
serve as an adjuvant in assisting the effects or facilitating
the delivery of the principal component. Entirely based on
TCM theory and NAFLD pathology, Salvia-Nelumbinis
naturalis (SNN) formulae (initially called Jiangzhi Granula)
was designed, in which Salviaeas being the principal
element and Nelumbinis, Rhizoma Polygoni Cuspidati,
Herba Artemisiae Scopariae the ancillary components.
We have shown that administration of SNN formulae,
together with behavioral intervention, to patients with
NAFLD for 24 weeks gave rise to a higher remission rate
as compared to behavioral intervention alone (76.56%
versus 52.54%) [8]. In addition, with all the cases observed,
SNN did not demonstrate any adverse effect during the
whole process [8]. These promising clinical observations
of the SNN formulae in ameliorating NAFLD have
prompted us to define mechanisms responsible for
SNN action. An UPLC-MS method has been established
to determine the main active components of SNN [9],
thus ensuring standardized application in clinical and
preclinical studies.
High calorie (HC) diet is a method that is extensively
used to induce hepatic steatosis and insulin resistance
in rats and mice [10-12], which resemble characteristics
of NAFLD in human. In this study, a rat model of
HC-induced NAFLD was used to examine the influence




HepG2 cells were purchased from the American Type
Culture Collection (ATCC) bioresource center (Manassas,
VA, USA). Dulbecco’s modified Eagle’s medium (DMEM),
fetal bovine serum (FBS), and penicillin and streptomycin
were from Biowest (Nuaillé, France). The main chemicalcomponents of the SNN extract protopanaxadiol,
tanshinone IIA, gypenoside, Salvianic acid A sodium,
and Salvianolic acid B were obtained from Shanghai
Winherb Medical Sci & Tech Development Co. Ltd.
(Shanghai, China). Pioglitazone were purchased from
Sigma (St. Louis, MO, USA). All other reagents were
of analytical grade.
Cell culture
HepG2 were cultured in DMEM supplemented with
10% heat-inactivated fetal FBS, penicillin at 100 U/mL,
and streptomycin at 100 μg/mL at 37°C in a 5% CO2
atmosphere. The experiments, started when the cells grew
to 80-90% confluence. Cellular steatosis was induced as
previously described [13], in brief, HepG2 cells were seeded
on 6-well plates 1× 105 cells/well, stimulated by a mixture
of 1 mmol/L FFA (the ratio of oleate to palmitate is 2:1) in
DMEM containing 1% BSA for 24 h. The steatotic cells
were then treated with the chemical components (at 5, 50,
and 500 μmol/L concentration for each component) for
another 24 h. The cells were stained with Oil-Red O and
imaged.
Preparation of extract of Salvia-Nelumbinisnaturalis
The Salvia-Nelumbinisnaturalis(SNN) formula composed
of Salviae (Danshen in China) as the principal element
and Nelumbinis (Heye in China), Rhizoma Polygoni
Cuspidati (Huzhang in China), Herba Artemisiae
Scopariae (Yinchen in China) as ancillary components.
The plant specimens were under a micro plant grinding
machine, triturated and blended to powder, and the
powder was then mixed with water/methanol (5:95, V/V) by
sonication (42 kHz, 30 min) using an ultrasonic processor
as described previously [9]. The main chemical components
of the SNN extract has been determined by UPLC-MS
system in previous publications [9].
Animals and study design
Male Wistar rats were obtained from Slac Animal
Laboratories (Shanghai, China), and housed under a
standard 12-h light–dark cycle (lights on at 7:00 AM) with
access to food and water ad libitum. After approximately
1-week acclimation, rats were placed on either standard
chow or HC (15% fat, 15% sucrose and 2% cholesterol) diet
for up to 12 weeks. During the last 4-week dieting, rats on
HC diet were divided into four groups – one group
continued on HC diet and the remainder three
groups were administered (through oral gavage, daily)
with pioglitazone (10 mg/kg body weight), Simvastatin
(4 mg/kg), and SNN extract (600 mg/kg), respectively.
Oral gavage of saline was applied to control rats. The
experimental protocols were approved by Shanghai
University of Traditional Chinese Medicine. Rats were
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and 24-h food intake were measured weekly.Oral glucose tolerance test and insulin tolerance test
Oral glucose tolerance test (OGTT) and insulin tolerance
test (ITT)were performed with rats at the end of dieting
using previously described methods [14]. Briefly, rats were
fasted for 6 h after the start of the light cycle, then orally
administered with glucose (1.5 g/kg body weight, for
OGTT) or intraperitoneally administrtered with insulin
(0.75u/kg body weight, for ITT), tail-vein blood samples
were collected at baseline and at indicated time intervals
(15, 30, 60, 90, and 120 min) after glucose/insulin
administration. Blood glucose levels were determined
with a diabetes monitoring strip (Lifescan One Touch, IN).
The curve was drawn and the area under the curve (AUC)
was calculated.Serum biochemical analysis
After fasting for 12 h, rats were anaesthetized with
sodium pentobarbital (100 mg/kg) and sacrificed, and
blood was collected from aorta abdominalis. Serum
TG, total cholesterol (TC), high density lipid-cholesterol
(HDL-c), low density lipid-cholesterol (LDL-c), free fatty
acids (FFA), fasting blood glucose (FBG), almandine
aminotransferase (ALT), and aspartate aminotransferase
(AST) were analyzed using the Hitachi full-automatic
system. Fasting insulin (FIN) was measured using the
standard radio-immunity kits (Puerweiye Bioengineering
Institute, Beijing, China).Hepatic histology assessment
Liver sections were stained with Hematoxylin and eosin
(HE) and Oil-Red O (Sigma, St. Louis, MO), the procedures
were performed according to previously describe methods
[15]. Briefly, the liver tissues were fixed in 10% neutral
buffered formalin for 24 h, dehydrated and embedded in
paraffin, the sections were cut, deparaffinized and stained
with HE. Snap frozen tissues were placed in optimal
cutting temperature compound and then sectioned
and stained with Oil-Red O.Table 1 Sequences of the primers used for amplification
of mRNA by PCR




β-actin CTGGAAGGTGGACAGTGAG GAGGGAAATCGTGCGTGACHepatic lipid and glycogen content
Liver TG was estimated as described previously [16].
Briefly, liver tissue (200 mg) was homogenized in 3 ml
of ethanol-acetone (1:1) mixture. The homogenate was
extracted over night at 4°C, and centrifuged for 15 min
at 3,000 rpm at 4°C. The organic layer was removed, TG
and cholesterol were measured using commercial kits
(Kangtai Bioengineering Institute, Beijing, China). A
standard kit (Jianchen tech, Nanjing, China) was used to
determine the hepatic glycogen concentration.RNA analysis
Total RNA was extracted from liver and hypothalamic
tissues by using a TRIzol Reagent (Invitrogen Corp.,
Carlsbad, CA) following the manufacturer’s instructions. A
reverse-transcription system (Promega Corp., Madison, WI)
was then used to transcribe the RNA. Semi-quantitative
reverse transcription polymerase chain reaction method was
performed using Mastercycler (Eppendorf, Inc., Germany).
The primer sequences are shown in Table 1. The mRNA
levels of all genes were normalized using β-actin as an
internal control.
Tissue sampling and western blot analyses
Frozen liver and hypothalamic tissues were homogenized in
Tissue Protein Extraction Reagent (Pierce Biotechnology,
Inc., Rockford, USA), with the addition of protease inhibitor
(Roche, Nutley, USA) and phosphatase inhibitor cocktail
(Roche, Nutley, USA). Protein concentrations were deter-
mined using the bicinchoninic assay reagents and the
micro-bicinchoninic assay method (Pierce Biotechnology,
Inc. Rockford, USA). For Western blot analysis, 100 μg
of protein were fractionated by 8-12% SDS-PAGE,
transferred onto a PVDF membrane (Bio-Rad, Hercules,
CA), Membranes were blocked with 5% skim milk in
Tris-buffered saline and probed with target primary and
secondary antibodies. Total and phosphorylated InsR
(Tyr1131), IRS1 (Ser302), Akt (Ser473) and SOCS3 anti-
bodies were purchased from Cell Signaling Technology
(Danvers, MA, USA), PKCε antibody was from Boster
company (Wuhan, China). β-actin and secondary anti-
bodies (from mouse or rabbit) conjugated to peroxidase
were purchased from Santa Cruz Biotechnology. The
targeted proteins were detected with ECL Detection Kit
(Millipore, Billerica, USA), images were taken and quali-
fied by Gel-Pro system (Tanon Technologies).For western
blot analysis, the amount of protein loaded was confirmed
by the Bradford method, and equal loading was verified by
staining with Ponceau S reagent (Sigma Chemical Co.)
and by determining the signal of β-actin.
Statistical analysis
For each outcome measure, a one-way analysis of
variance was performed (SPSS 18.0) for each animal group
studied (n = 8). A significant main effect (p < 0.05 or
p < 0.01) was followed-up with Student-Newman-Kuel
A B C D
E F G
Figure 1 Effects of SNN chemical components on HepG2 cellular steatosis. HepG2 cells were stimulated by a mixture of 1 mmol/L FFA (the
ratio of oleate to palmitate is 2:1) 24 h. The steatotic cells were then treated with the chemical components for another 24 h. The cells were
stained with Oil-Red and observed under microscope (200×). A: Control; B: Model; C: protopanaxadiol 500 μmol/L; D: tanshinone IIA 50 μmol/L; E:
gypenoside 50 μmol/L; F: Salvianic acid A sodium 500 μmol/LG: Salvianolic acid B 50 μmol/L.
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standard error (SE), and p < 0.05 denotes a statistically
significant difference.
Results
Effect of SNN components on steatosis in HepG2 cells
The 24 h incubation HepG2 cells with FFA induced
significant lipid accumulation in the cells compared to that
of control cells (Figure 1A&B). Treatment with different
SNN components to the cell could reduce the lipid to
different extent (Figure 1C-G). Notably, protopanaxadiol
(500 μmol/L), Salvianic acid A sodium (500 μmol/L),
and Salvianolic acid B (50 μmol/L) showed the obvious
improvement of the steatosis, indicating the promising
effect of SNN components on steatosis in HepG2 cells.
Parabolic response of serum lipids during hepatosteatosis
progressing
Male Wistar rats placed on a HC diet exhibited the
expected hypertriglyceridemia, hypercholesterolemia,
hyperglycemia, hyperinsulinemia, hyperleptinemia, andTable 2 Liver Parameters
Parameters 8-week dieting Post
Chow HC Chow
Body weight (g) 392.6 ± 5.9 433.3 ± 6.1†† 436.0
Post 4-week body weight gain (g) ND ND 43.38
Liver weight (g) 9.9 ± 0.07 18.7 ± 0.40†† 14.05
Liver/Body weight ratio (%) 2.69 ± 0.02 4.31 ± 0.03 3.15 ±
Food intake (kal/d) 73.5 ± 3.1 102.2 ± 3.8†† 75.60
Liver TG (mg/g) 20.2 ± 0.6 58.3 ± 1.2†† 24.1 ±
Liver glycogen (mg/g) ND ND 46.7 ±
ALT (u/l) 51.6 ± 2.8 54.4 ± 2.7 56.04
AST (u/l) 125.5 ± 12.9 88.8 ± 3.6 110.1
Values are means ± SE (n = 6–8 per group). ††p < 0.01relative to 8-weekunder chow
##p < 0.01, versus12-weekHC diet. TG, triglyceride; ALT, alanine transaminase; AST, asincreased body weight (Table 2) as compared to age
matched controls. The serum FFA levels were increased by
30% at the end of 8-week of HC dieting (Table 3); however,
the increased fasting FFA concentration upon prolonged
HC dieting was not associated with increase in fasting
serum TG. Rather, fasting serum TG exhibited gradual
decline from 2-week of HC dieting (Figure 2A), even
though the hepatic TG content remained high (Table 2).
At the end of 12-week of HC dieting, the serum TG
concentration was decreased to a level that was lower than
that in chow diet-fed animals (chow diet: 1.62 ± 0.80 mM,
HC diet: 0.98 ± 0.16 mM; P < 0.01). Similarly, serum TC
level also showed a trend of decline after the max at
1-week checkpoint, while hepatic cholesterol reached
the plateau (Figure 2B). The decrease in plasma TG
probably reflects the compromised ability of the liver
to produce VLDL after prolonged HC dieting.
Effect of SNN on liver steatosis
The 8-week HC fed rats developed hepatomegaly; the
mean liver weight and liver weight/body weight ratio4-week treatment
HC HC + Pio HC + SNN HC + Sim
± 6.5 487.1 ± 10.7** 510.4 ± 11.5 477.3 ± 9.5 477.9 ± 18.9
± 3.82 53.88 ± 6.81* 78.73 ± 8.24# 45.00 ± 5.96 49.50 ± 7.88
± 0.39 20.08 ± 0.67** 18.55 ± 0.48 19.78 ± 0.70 20.72 ± 1.07
0.02 4.12 ± 0.17 3.64 ± 0.14 4.14 ± 0.22 4.32 ± 0.22
± 4.0 110.24 ± 5.2** 112.36 ± 3.8 106.54 ± 6.1 104.88 ± 5.6
0.6 67.2 ± 2.6** 48.1 ± 0.9## 47.8 ± 1.3## 46.2 ± 13##
4.57 16.8 ± 1.33** 30.8 ± 1.95## 31.02 ± 1.62## ND
± 8.91 52.28 ± 5.60 62.51 ± 8.68 70.19 ± 12.76 66.4 ± 8.75
± 10.79 91.4 ± 12.59 90.2 ± 15.35 132.4 ± 87.98 89.7 ± 8.70
diet,*p < 0.05, **p < 0.01relative to 12-weekunder chow diet; #p < 0.05,
partate transaminase; ND, not determined.
Table 3 Serum Parameters
Parameters 8-week dieting Post 4-week treatment
Chow HC Chow HC HC + Pio HC + SNN HC + Sim
TG (mM) 1.12 ± 0.08 1.90 ± 0.14†† 1.62 ± 0.80 0.98 ± 0.16** 0.88 ± 0.23 1.53 ± 0.38## 1.41 ± 0.22##
TC (mM) 1.59 ± 0.04 2.95 ± 0.13†† 1.93 ± 0.18 2.53 ± 0.18** 2.43 ± 0.13 2.44 ± 0.14 2.46 ± 0.15
HDL-c (mM) 1.02 ± 0.01 0.80 ± 0.04†† 1.66 ± 0.15 0.95 ± 0.09** 1.12 ± 0.12# 0.99 ± 0.06 0.88 ± 0.03
LDL-c (mM) 0.32 ± 0.01 1.60 ± 0.08†† 0.25 ± 0.07 1.47 ± 0.18** 1.19 ± 0.16# 1.17 ± 0.15# 1.31 ± 0.11
FFA (u/l) 1792 ± 81.6 2414 ± 145†† 1966 ± 107 2562 ± 153** 2162 ± 136# 2100 ± 162# 2476 ± 174
FBG (mM) 5.0 ± 0.11 8.8 ± 0.26†† 5.5 ± 0.26 9.8 ± 0.26** 9.6 ± 0.33 9.7 ± 0.29 ND
FIN (u/l) 36.7 ± 1.27 194.5 ± 25.47†† 56.4 ± 14.6 226.3 ± 19.7** 208.0 ± 19.4 219.3 ± 20.2 ND
Values are means ± SE (n =6-8 per group). ††p < 0.01relative to 8-weekunder chow diet,**p < 0.01relative to 12-weekunder chow diet; #p < 0.05, ##p < 0.01,
versus12-weekHFHS diet.TG, triglyceride; TC, total cholesterol; HDL-c, high density lipoprotein cholesterol; LDL-c, low density lipoprotein cholesterol; FFA, free fatty
acid; FBG, fasting blood glucose, FIN, fasting insulin; ND, not determined.
Zhang et al. Journal of Translational Medicine 2014, 12:236 Page 5 of 11
http://www.translational-medicine.com/content/12/1/236were 2- and 1.6-fold, respectively, higher than that in
age matched rats fed chow diet (Table 2). Massive
macro- vesicular steatosis were observed in liver sections in
accordance with the increase of hepatic TG concentrations,
indicating the development of fatty liver in HFHS fed rats.
After 4 weeks of SNN treatment, however, hepatic steatosis
was markedly reduced, despite the persistence of
hepatomegaly (Figure 3). Hepatic TG concentrations inA
B
Figure 2 Parabolic decline of serum triglyceride level upon
hepatosteatosis progress. Male Wistar rats (6 weeks of age) placed
on a high-calorie (HC) diet or normal chow diet, blood was collected
at 0, 2, 4, 6, 8, 10,12 week, serum was separated and analysed. A:
The change of serum TG upon HC feeding; B: The change of serum
TC upon HC feeding.SNN-treated rats were decreased by approximately 30% as
compared to that of non-treated control animals, and the
effect of SNN treatment in reducing hepatic TG content
was comparable to that of Simvastatin and Pioglitazone
(Figure 3, Table 2).
Effect of SNN on serum lipid profile
Analysis of serum lipoproteins revealed that the hyperchol-
esterolemia in rats fed the HC diet was associated with
increased LDL-c and decreased HDL-c (Table 3), typical
phenotypes of diabetic dyslipidemia. Rats fed with HC
diet for 12 weeks also showed increased FFA levels in
circulation (Table 3). The 4-week SNN treatment normal-
ized the lipid profile to a certain extent, as manifested by
decreased LDL-c and FFA (Table 3).
Increase hepatic fat content often correlates with
increased TG secretion in the form of VLDL. However,
decrease in serum TG is often observed as fatty liver
progresses as a result of impaired hepatocellular function.
The decrease in serum TG in HC diet-fed rats was re-
versed by 4-week SNN treatment (Table 3), suggesting res-
toration of normal hepatic TG secretion and hepatocellular
function.
Effect of SNN on insulin sensitivity
HC diet-fed rats showed hyperinsulinemia and hyper-
glycemia, elevated HOMA-IR and impaired glucose toler-
ance compared with chow diet-fed controls (Table 2),
indicative of insulin resistance. With 4-week SNN treat-
ment, decrease in blood glucose levels was observed as
compared with that in untreated HC rats at all time points
(from 30 min through 2 h) during the OGTT experiment
(Figure 4A). Accordingly, decrease in OGTT-AUC values
ensured in the SNN-treated rats (Figure 4B). As for ITT,
there is no significant difference of the blood glucose
between control group and HC diet group (Figure 4C),
and so did the ITT-AUC values (Figure 4D). The 12-week
HC feeding also resulted in a 60% decrease of hepatic
glycogen content as compared to chow diet-fed rats,
Chow HC HC+Pio HC+SNN HC+SimA
B
Figure 3 The effect of SNN on HC diet induced hepatosteatosis. Male Wistar rats (6 weeks old) were placed on chow diet or HC diet for
8 weeks followed by the 4-week SNN intervention. The livers were excised, processed and stained with hematoxylin-eosin (HE) (A) and Oil Red O
(B) (upper panels, chow diet; lower panels, HC diet). Images are magnified 200 × .
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glycogen content (Figure 4E), and the effect of SNN
was comparable to that of pioglitazone.
In comparison to that in rats fed chow diet, the levels of
InsR and IRS mRNA and IRS1 phosphorylation were
decreased in rats fed HC diet (Figure 5). To demonstrate
the effect of SNN in regulating insulin signalling transduc-
tion, we analysed molecular expression in insulin signalling
pathway. With SNN supplement, the phosphorylated InsR
and IRS2 levels were not significantly different from that of
untreated rats, but IRS1 mRNA expression (Figure 5A) and
phosphorylation protein (Figure 5B) dramatically increased,
indicating the restoration of IRS1 activity. Akt is one of the
downstream molecules of IRS in insulin pathway, which is
critical in glucose homeostasis because it controls both
gluconeogenesis and glycogen synthesis. The Akt phosphor-
ylation in the 12-week HC rats were remarkably decreased,
which may partially explain the 60% decrease of hepatic
glycogen content compared with the chow diet animals.
SNN increased the hepatic Akt phosphorylation (Figure 5A)
and glycogen content (Figure 5B) with the 4-week treat-
ment. These data together suggest strongly an improvement
in hepatic insulin sensitivity with SNN treatment.
Effect of SNN on regulatory molecules of insulin pathway
The abnormalities in lipid and glucose metabolism
upon HC dieting were also associated with activationof regulatory signaling pathways. HC dieting induced
increased expression of SOCS3, a negative regulator insulin
signaling. SOCS3 has been shown interfering insulin
signaling by competitively binding to the InsR, affecting
IRS phosphorylation [17], or promoting ubiquitin-mediated
IRS degradation [18]. Indeed, upon HC dieting, SOCS3
expression in the liver was up-regulated upon 12-week HC
dieting, and with 4-week SNN treatment, SOCS3 expres-
sion was significantly decreased (Figure 6), indicating SNN
has an inhibitory effect on SOCS3 expression, and the
change was also consistent with IRS expression. In addition
to SOCS3, the lipid-dependent kinases, PKC family has
been reported to inhibit several components of the insulin
signaling pathway, among the 10 isoforms, PKCε is the
isoform most often implicated in association with hepatic
insulin resistance [19]. Western blot analysis revealed that
PKCε was markedly increased along with the development
of hepatic steatosis, however, the regulation of SNN on
PKCε was statistically no significant (Figure 6).
Discussion
Natural plant products provide a number of promising
therapeutic agents. TCM uses a large variety of such herbal
products and provides a rational prescription approach that
targets the pattern of the syndrome, which is the essence of
its therapeutic strategy. A lipid-lowering agent SNN was




Figure 4 The effect of SNN on glucose and insulin tolerance and glycogen. Male Wistar rats (6 weeks old) were placed on chow diet or HC
diet for 8 weeks followed by the 4-week SNN intervention. OGTT and ITT were conducted after 6 h fasting, glucose (1.5 g/kg body weight) was
orally administered, or insulin (0.75u/kg body weight) was intraperitoneally injected, tail-vein blood samples were collected at baseline and at indicated
time intervals (15, 30, 60, 90, and 120 min) after glucose administration. Blood glucose levels were determined with a diabetes monitoring strip. OGTT
and ITT curves were drawn (A, C) and AUC were calculated (B, D). The livers were excised and glycogen content was detected (E). Data (mean ± SE)
are presented, **P < 0.01 relative to control group, #P < 0.05, ##P < 0.01 in comparison to HC group.
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therapeutic option for the development and progression
of NAFLD [20]. The current study has demonstrated
the SNN chemical components can reduce FFA-induced
cellular steatosis. While HC diet-induced NAFLD rats
exhibited dyslipidemia, hyperinsulinemia, and insulin
resistance with concomitant hepatic steatosis, SNN
reduced serum levels of LDL-c, and hepatic levels of
TG with an attenuation of hepatic steatosis in HCdiet-induced rats. These results together indicate that
SNN is an effective drug for treating NAFLD.
Hepatic steatosis is the hallmark of NAFLD, and TG
accumulation in hepatocytes is considered to be the
major pathogenic trigger in the development of NAFLD
[21]. In the current study, SNN components could improve
FFA-induced steatosis in HepG2 cells, and animal studies
showed that SNN could significantly attenuate the HC diet-
induced hepatic steatosis and the lipid accumulation, both
AB
Figure 5 The effect of SNN on InsR, IRS1/2 and Akt expression in the liver. Male Wistar rats (6 weeks old) were placed on chow diet or HC diet for
8 weeks followed by the 4-week SNN intervention. Livers were collected, the mRNA expression of InsR and IRS1/2 was detected through PCR (A), and the
protein expression of Total and phosphorylated InsR (Tyr1131), IRS1 (Ser302), Akt (Ser473) was analysed by Western blots (B). Data (mean ± SE) are presented
as relative expression levels compared to that of control group. **P< 0.01 relative to control group, ##P< 0.01 in comparison to HC group.





Figure 6 The effect of SNN on SOCS3 and PKCε expression in the liver. Male Wistar rats (6 weeks old) were placed on chow diet or HC diet
for 8 weeks followed by the 4-week SNN intervention. Livers were collected, the protein expression of SOCS3 and PKCε was analysed by Western
blots. Data (mean ± SE) are presented as relative expression levels compared to that of control group. **P < 0.01 relative to control group, #P < 0.05 in
comparison to HC group.
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Liver also overproduces several atherogenic factors
under nutritional stress [22,23], in this study, the levels of
and LDL-c were significantly decreased in SNN-treated
rats, which partly confirms the protective nature of SNN
against atherogenic risk.
NAFLD is associated with dyslipidemia, increased
hepatic fat content often (but not always) correlates
with increased hepatic TG secretion. The only route
for TG export from hepatocytes is via the assembly
of VLDL. However, as NAFLD progresses, the production
of VLDL might decrease secondary to the impairment of
hepatocellular function. Studies of seven patients with
biopsy proven NASH showed decreased apolipoprotein B
(apoB, the primary apolipoproteins of VLDL) production
rate (by 50%) as compared with obese or lean controls
without NAFLD [24]. We have observed a parabolic
response of serum TG level during diet-induced fatty liver
progression, indicating the impairment of hepatocellular
function. The mechanisms responsible for the parabolic
change of serum TG is unclear. Nevertheless, 4-week
SNN treatment results in an improved hepatocellular
function, evidenced by the restoration of serum TG.
Cell culture and animal studies showed that, although
moderate FFA overload increases VLDL secretion,
prolonged FFA exposure induced ER stress and resulted
in decreased VLDL secretion [25]. Whether or not SNN
treatment can reduce ER stress remains to be determined.
The two-hit and multi-hit hypotheses postulate that
insulin resistance is the initial trigger of the pathogenesis of
NAFLD [26,27]. Insulin sensitivity/resistance is usuallytested on glucose metabolism. HOMA-IR is largely used in
epidemiological studies because it only requires measuring
FIN and FBG, and OGTT indices are frequently used in
clinical practice [28,29]. Both tests are commonly
used to measure whole-body and peripheral insulin
resistance. The results of the experiment in this study
showed an increase of HOMA-IR and OGTT indices,
which signify insulin insensitivity in NAFLD rats. SNN
markedly reduces OGTT indices, but fails to inhibit
HOMA-IR increase, which suggests that SNN may not
completely reverse whole-body insulin resistance involved
in NAFLD.
Insulin has a strong influence on lipogenesis and
glucose homeostasis as well [30,31]. The failure of hepato-
cytes to respond to insulin contributes to the development
of glucose intolerance, whereas lipogenesis, which is posi-
tively regulated by insulin, remains sensitive to insulin and
is driven excessively by the compensatory hyperinsulinemia
[32]. Thus, the failure of the insulin system enhances
hepatic glucose and lipid production [33]. Hepatic insulin
resistance is strongly associated with NAFLD and is
characterized by the impairment of glycogenesis with an
increase of glucogenesis and glycogenolysis [34]. Glycogen
synthesis represents a major pathway for glucose disposal
after insulin stimulation, and increased hepatic glycogen
synthesis and glycogen content are involved in enhanced
insulin sensitivity [35]. Previous studies suggested that
glycogen in the liver is important to maintain physical
performance during prolonged exercise, and that glycogen
synthesis is reduced in type 2 diabetes mellitus [36,37]. The
present study demonstrated that SNN increases hepatic
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insulin signalling transduction in NAFLD rats. The
decrease in liver InsR and IRS expression is in accordance
with the impairment of the hepatic insulin pathway and
represents the therapeutic targets of insulin resistance
[16]. This finding indicates that the improvement of
hepatic insulin sensitivity contributes to the reduction
of hepatic lipid accumulation in NAFLD rats. Therefore,
hepatic insulin resistance is an important target for SNN
therapy for HC diet-induced NAFLD.
Hepatic insulin resistance is also associated with activation
of regulatory signaling pathways. Among the regulatory
molecules, SOCS3 has been shown interfering insulin
signaling by competitively binding to the InsR, affecting IRS
phosphorylation [17], or promoting ubiquitin-mediated IRS
degradation [18]. In addition to SOCS3, the isoforms of
PKC family have wide-ranging roles in signal transduction,
including the positive and negative modulation of insulin
action, and they are dependent on diacylglycerol
(DAG) for full activation [38]. PKCε is the isoform most
often implicated in association with hepatic insulin resist-
ance, PKCε in liver may affect its ability to phosphorylate
the substrates or InsR trafficking in hepatocytes [39].
In our study, both SOCS3 and PKCε were signifi-
cantly increased with the development of NAFLD,
which was consistent with the impairment of insulin
signaling pathway, indicating these regulatory mole-
cules may contribute to the insulin resistance. SNN
showed improvement on SOCS3 expression, but not
that of PKCε, the potential mechanisms need to be
further explored, other isoforms of PKC family may
also involved in the regulatory process.
Thiazolidinediones are insulin-sensitizing agents that
improve insulin sensitivity and are effective for the
treatment of specific metabolic defects. However, the
use of thiazolidinediones for NAFLD treatment raises a
number of safety concerns [40,41]. In this study, pioglita-
zone shows beneficial effects on NAFLD rats, but causes
body weight gain, which is in accordance with the results
in reported clinical studies [42,43]. Moreover, pioglitazone
may predispose at-risk patients to exacerbated heart
failure [44]. Because of these side effects in addition
to other potential risks, efficacy of some of the insulin
sensitizers in NAFLD therapy is limited. This study shows
that the two regimens for treating NAFLD rats have
similar effects. The results also show that SNN rats
do not exhibit any body weight gain, which signifies
that SNN is safe and suitable for long-term use.
Conclusions
The results show that SNN exerts a protective effect on
steatosis in HepG2 cells and HC diet-induced NAFLD in
rats. This protective effect may be due to attenuation of
hepatic insulin resistance.Competing interests
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